eFFECTOR Appoints Mike Byrnes as Chief Financial Officer

    NEXT STORY
    Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
    PREV STORY
    Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Five Prime to Present Preclinical Data at 2016 SITC Annual Meeting For Novel Tetravalent Anti-GITR Antibody

    SOUTH SAN FRANCISCO, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

    author_avatar
    NASDAQ Market News

    Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels

    author_avatar
    NASDAQ Market News

    Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    -- Global Phase 3 URIROX-1™ Trial Ongoing; Expect to Initiate Second Phase 3 Study, ...

    author_avatar
    NASDAQ Market News